SONN Key Statistics, Chart & Performance
The current stock price of SONN is 1.26 USD. In the past month the price decreased by -68.73%. In the past year, price decreased by -40%.
SONN Technical Analysis
SONN Financial Highlights
Over the last trailing twelve months SONN reported a non-GAAP Earnings per Share(EPS) of -7.23. The EPS increased by 70.17% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -659.57% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
SONN Forecast & Estimates
7 analysts have analysed SONN and the average price target is 20.4 USD. This implies a price increase of 1519.05% is expected in the next year compared to the current price of 1.26.
SONN Ownership
SONN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.36 | 390.15B | ||
| AMGN | AMGEN INC | 14.83 | 174.63B | ||
| GILD | GILEAD SCIENCES INC | 14.87 | 151.07B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.19 | 115.36B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.86 | 79.76B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 725.41 | 48.88B | ||
| INSM | INSMED INC | N/A | 34.92B | ||
| NTRA | NATERA INC | N/A | 32.83B | ||
| BIIB | BIOGEN INC | 10.65 | 26.16B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 23.19B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.07 | 20.53B | ||
| INCY | INCYTE CORP | 16.11 | 20.31B |
Related stock screener links
About SONN
Company Profile
Sonnet BioTherapeutics Holdings, Inc. is a clinical stage biotechnology company, which engages in the innovation of biologic medicines. The company is headquartered in Princeton, New Jersey and currently employs 13 full-time employees. The company went IPO on 2005-07-27. The Fully Human Albumin Binding (FHAB), a technology which utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its FHAB is designed to specifically target tumor and lymphatic tissue. The firm's lead program, SON-1010, or IL-12-FHAB, is in development for the treatment of solid tumors and ovarian cancer. SON-1010 is being evaluated in an ongoing Phase 1/2a study, in combination with atezolizumab (Tecentriq) for the treatment of platinum-resistant ovarian cancer (PROC). The firm is also evaluating its second program, SON-1210, an IL12-FHAB-IL15 for solid tumor. Its SON-080 program is a low dose of rhIL-6 in development for Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Diabetic Peripheral Neuropathy (DPN).
Company Info
SONNET BIOTHERAPEUTICS HOLDI
100 Overlook Center, Suite 102
Princeton NEW JERSEY 08540 US
CEO: Pankaj Mohan
Employees: 13
Phone: 16093752227
SONNET BIOTHERAPEUTICS HOLDI / SONN FAQ
Can you describe the business of SONNET BIOTHERAPEUTICS HOLDI?
Sonnet BioTherapeutics Holdings, Inc. is a clinical stage biotechnology company, which engages in the innovation of biologic medicines. The company is headquartered in Princeton, New Jersey and currently employs 13 full-time employees. The company went IPO on 2005-07-27. The Fully Human Albumin Binding (FHAB), a technology which utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its FHAB is designed to specifically target tumor and lymphatic tissue. The firm's lead program, SON-1010, or IL-12-FHAB, is in development for the treatment of solid tumors and ovarian cancer. SON-1010 is being evaluated in an ongoing Phase 1/2a study, in combination with atezolizumab (Tecentriq) for the treatment of platinum-resistant ovarian cancer (PROC). The firm is also evaluating its second program, SON-1210, an IL12-FHAB-IL15 for solid tumor. Its SON-080 program is a low dose of rhIL-6 in development for Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Diabetic Peripheral Neuropathy (DPN).
What is the stock price of SONNET BIOTHERAPEUTICS HOLDI today?
The current stock price of SONN is 1.26 USD. The price decreased by -59.35% in the last trading session.
Does SONN stock pay dividends?
SONN does not pay a dividend.
What is the ChartMill technical and fundamental rating of SONN stock?
SONN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Which stock exchange lists SONN stock?
SONN stock is listed on the Nasdaq exchange.
Should I buy SONN stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on SONN.